Of note, KLF4-mutated meningiomas exhibit higher sensitivity to mTOR inhibitors such as temsirolimus [48], underlining the potential role of the PI3K/AKT/mTOR pathway as potential treatment target in meningioma. This evidence concerns the gene KLF4 and meningioma.